This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.62% per year. These returns cover a period from January 1, 1988 through June 2, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
4 Sector ETFs to Ride on Strong Beat Ratios
by Sanghamitra Saha
Sector ETFs with strong beat ratios in fourth-quarter earnings.
Biotech Crushing the Market: Best ETFs & Stocks YTD
by Sweta Killa
The recent developments are fueling growth in the biotech companies, leading to a rally in their share prices and impressive levels of momentum in biotech ETFs.
Biotech ETF (BBC) Hits New 52-Week High
by Sweta Killa
This biotech ETF hits a new 52-week high. Are more gains in store for this ETF?
M&A Waves Pushing Biotech ETFs Higher
by Sweta Killa
The new tax legislation has enticed U.S. companies to bring offshore cash back home, sparking waves of mergers and acquisitions.
Tax Reform: A Boon or Bane for Small-Cap ETFs?
by Sanghamitra Saha
Small-cap ETFs may be gaining on tax cut hopes but all is not rosy in the tax blueprint for the pint-sized stocks.
Value Biotech ETFs to Buy Now
by Sanghamitra Saha
A few reasons why you should buy value biotech ETFs for 2018
Top and Flop Sector ETFs of Q3
by Sanghamitra Saha
Inside the best and worst performing ETF areas of the third quarter.
Best Sector ETF of Q3 and its Top-Performing Stocks
by Sweta Killa
Inside the top performing stocks of top U.S.-focused ETF of Q3.
Volatility Shakes Market: Top and Flop ETFs Over a Month
by Sweta Killa
The long list of woes started with escalating tensions between the United States and North Korea from word of war.
Top and Flop ETFs of August: Metals Gain, Crops Crash
by Sanghamitra Saha
Inside the best and worst performing ETF areas of the month of August.
Biotech ETFs Soar on Gilead-Kite Deal
by Sanghamitra Saha
Gilead Sciences boosted the biotech ETF world on August 28 by announcing the buyout news of Kite Pharma.
The Zacks Analyst Blog Highlights: BioShares Biotechnology Clinical Trials, PowerShares Dynamic Semiconductors Fund, PowerShares S&P SmallCap Utilities Portfolio, PowerShares S&P SmallCap Energy Fund and Guggenheim S&P SmallCap 600 Pure V
by Zacks Equity Research
The Zacks Analyst Blog Highlights: BioShares Biotechnology Clinical Trials, PowerShares Dynamic Semiconductors Fund, PowerShares S&P SmallCap Utilities Portfolio, PowerShares S&P SmallCap Energy Fund and Guggenheim S&P SmallCap 600 Pure Value
The Zacks Analyst Blog Highlights: BioShares Biotechnology Clinical Trials, Global X MSCI Argentina, iPath S&P 500 VIX Short-Term Futures, iPath Bloomberg Natural Gas Subindex Total Return and iPath Global Carbon
by Zacks Equity Research
The Zacks Analyst Blog Highlights: BioShares Biotechnology Clinical Trials, Global X MSCI Argentina, iPath S&P 500 VIX Short-Term Futures, iPath Bloomberg Natural Gas Subindex Total Return and iPath Global Carbon
Best and Worst Zones of Q1 and Their ETFs
by Sweta Killa
Most corners of ETF investing have performed exceptionally well in Q1 while a few areas are lagging.
5 Top Performing Stocks of the Best ETF of Q1
by Sweta Killa
Inside the top performing stocks of biotech ETF that tops the list of the best performing ETFs of Q1.
The Zacks Analyst Blog Highlights: BioShares Biotechnology Clinical Trials Fund, Guggenheim S&P SmallCap 600 Pure Value ETF, PowerShares S&P SmallCap Materials Fund, Health Insurance Innovations and Airgain
by Zacks Equity Research
The Zacks Analyst Blog Highlights: BioShares Biotechnology Clinical Trials Fund, Guggenheim S&P SmallCap 600 Pure Value ETF, PowerShares S&P SmallCap Materials Fund, Health Insurance Innovations and Airgain
How to Find Winning Biotech Stocks
by Tracey Ryniec
The biotechs are a gamble but here are some guidelines to lessen the risk.